Neurizon Raises $5m via Institutional Placement

Highlights:

 · Firm commitments secured to raise $5m through the issue of new fully paid ordinary shares at $0.12 per share

· In addition, the Board and management will subscribe for $0.2m under the Placement, $130,000 of which is subject to shareholder approval

· The Placement was strongly supported by both new and existing institutional investors

· Strengthened balance sheet supports preparation for entry into the HEALEY ALS Platform Trial in Q4 CY25, pending FDA clearance of Company’s IND

· Placement proceeds will also be used to advance pre-clinical programs, GMP manufacturing, regulatory filings and working capital

It is a 18% discount to existing SP but it has put $5.2 Million into the coffers which certainly helps 

NUZ have released the following announcement RE their drug NUZ-001:

US Patent granted for NUZ-001 for the treatment of Neurodegenerative Diseases Highlights:

 Patent granted by the USPTO covering the use of Neurizon’s lead drug candidate, NUZ-001, in neurodegenerative diseases and cancer

 Granted patent provides specific protection for NUZ-001 and structurally related compounds used in treatments for mTOR pathway-related diseases in the US market until 2039

 Considerably strengthen Neurizon’s commercial potential and provides a strong framework for any future licensing negotiations

 Patent grant follows FDA Orphan Drug Designation (ODD) for NUZ-001 in May 2024, further enhancing the Company’s IP estate and market position for NUZ-001 as the clinical trial pipeline advances

At this stage the Phase 2 Healey trial is still held up by the FDA but hopefully in the next few weeks NUZ will have an answer back in regards to the actual reason for the hold so they can move ahead with trial.